Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer
Authors:
- Vikram MalhiVMVikram Malhi
- Priya AgarwalPAPriya Agarwal
- Mary R. GatesMGMary R. Gates
- Lichuan LiuLLLichuan Liu
- Jianshuang WangJWJianshuang Wang
- Tom De BruynTBTom De Bruyn
- Scott LamSLScott Lam
- Jennifer Eng-WongJEJennifer Eng-Wong
- Pablo Perez-MorenoPPPablo Perez-Moreno
- Ya-Chi ChenYCYa-Chi Chen
- Jiajie YuJYJiajie Yu
Open Access
- 15 December 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (12) , 2551-2559
Abstract
Purpose: We describe the clinical pharmacology characterization of giredestrant in a first-in-human study. Experimental Design: This phase Ia/Ib dose-escalation/-expansion study (NCT03332797) evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of giredestrant in estrogen receptor–positive HER2-negative locally advanced/metastatic breast cancer. The single-agent dose-escalation stage evaluated giredestrant 10, 30, 90, or 250 mg once daily. The dose-expansion stage evaluated single-agent giredestrant at 30, 100, and 250 mg once daily. Dose-escalation and -expansion phases also evaluated giredestrant 100 mg combined with palbociclib 125 mg. Results: Following single-dose oral administration, giredestrant was rapidly absorbed and generally showed a dose-proportional increase in exposure at doses ranging from 10 to 250 mg. At the 30 mg clinical dose, maximum plasma concentration was 266 ng/mL (50.1%) and area under the concentration–time curve from 0 to 24 hours at steady state was 4,320 ng·hour/mL (59.4%). Minimal giredestrant concentrations were detected in urine, indicating that renal excretion is unlikely to be a major elimination route for giredestrant. Mean concentration of 4beta-hydroxycholesterol showed no apparent increase over time at both the clinical dose (30 mg) and a supratherapeutic dose (90 mg), suggesting that giredestrant may have low CYP3A induction potential in humans. No clinically relevant drug–drug interaction was observed between giredestrant and palbociclib. Giredestrant exposure was not affected by food and was generally consistent between White and Asian patients. Conclusions: This study illustrates how the integration of clinical pharmacology considerations into early-phase clinical trials can inform the design of pivotal studies and accelerate oncology drug development. Significance: This work illustrates how comprehensive clinical pharmacology characterization can be integrated into first-in-human studies in oncology. It also demonstrates the value of understanding clinical pharmacology attributes to inform eligibility, concomitant medications, and combination dosing and to directly influence late-stage trial design and accelerate development.Keywords
All Related Versions
Funding Information
- N/A (N/A)
This publication has 17 references indexed in Scilit:
- The Drug-Dosing Conundrum in Oncology — When Less Is MoreNew England Journal of Medicine, 2021
- GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast CancerJournal of Medicinal Chemistry, 2021
- Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).Journal of Clinical Oncology, 2021
- Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer TherapyClinical and Translational Science, 2019
- Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug DevelopmentClinical and Translational Science, 2017
- Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3ADrug Metabolism Reviews, 2016
- Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)The Oncologist, 2016
- Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancerEuropean Journal of Cancer, 2011
- Confidence Interval Criteria for Assessment of Dose ProportionalityPharmaceutical Research, 2000
- Predictability of the effects of race or ethnicity on pharmacokinetics of drugsInt. Journal of Clinical Pharmacology and Therapeutics, 2000